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Gregory L. Moneta, MD, Section EditorEffect of Ramipril on Walking Times and Quality of Life Among
Patients With Peripheral Artery Disease and Intermittent
Claudication. A Randomized Controlled Trial
Ahimastos AA, Walker PJ, Askew C, et al. JAMA 2013;309:453-60.
Conclusion: In patients with intermittent claudication, 24 weeks of
treatment with ramipril improves pain-free and maximum treadmill walking
times compared with placebo and is associated with a signiﬁcant increase in
the physical functioning component of the Short-Form 36 Health Survey
(SF-36; Quality Metrics, Lincoln, RI).
Summary: Drug treatments to improve walking distance in patients
with intermittent claudication generally have limited efﬁcacy. Increased
walking distances of between 12% and 16% can be expected. Of the drugs
approved for treatment of intermittent claudication by the United States
(U.S.) Food and Drug Administration for use in the U.S., pentoxifylline
and cilostazol increase walking distance by 15% and 25%, respectively
(Stevens JW et al, Br J Surg 2012;99:1630-8). A previous pilot study reported
that ramipril, an angiotensin-converting enzyme (ACE) inhibitor, improves
treadmill assessed pain-free and maximum walking time (Ahimastos AA et
al, Ann Intern Med 2006;144:660-4). Other trials of ACE inhibitors in
patients with intermittent claudication have been equivocal. The authors,
therefore, performed this investigator-initiated trial to examine the associa-
tion of ramipril therapy for 24 weeks on walking distance and health-related
quality of life. To make the study as generalizable as possible, patients with
diabetes, aortoiliac, and infrainguinal disease were included. This was
a randomized, double-blind, placebo-controlled trial conducted in 212
patients with peripheral arterial disease. Patients were a mean age of 65.5
years (standard deviation, 6.2 years). The trial was initiated in May 2008
and completed in August of 2011 and was conducted at three hospitals
in Australia. Patients were randomized to receive 10 mg/d ramipril (n ¼
106) or matching placebo (n ¼ 106) for 24 weeks. The main outcome
measures were maximum and pain-free walking times recorded during a stan-
dard treadmill test.Walking ability was assessed with theWalking Impairment
Questionnaire. Quality of life was assessed with the SF-36. Compared with
placebo at 6 months, ramipril was associated with a 70-second (95% conﬁ-
dence interval [CI], 60-89 seconds) increase in mean pain-free walking
time (P < .001). Maximum walking time increased a mean of 255 seconds
(95% CI, 215-195 seconds) compared with placebo in those receiving ram-
ipril (P < .001). Ramipril compared with placebo also improved Walking
Impairment Questionnaire median distance score by 13.8 (95% CI, 12.2-
15.5), speed score by 13.3 (95% CI, 11.9-15.2), and stair climbing score
by 25.2 (95%CI, 25.1-29.4; P< .001 for all comparisons). The SF-36 overall
median physical component summary score improved by 8.2 (95% CI,
3.6-11.4; P ¼ .02) in the ramipril group compared with placebo. Ramipril
did not affect the SF-36 median mental component summary score.
Comment: This is the ﬁrst study with adequate power to demonstrate
treatment with an ACE inhibitor can be associated with improved treadmill
walking performance in patients with intermittent claudication secondary to
atherosclerotic disease. Whereas the mechanism of beneﬁt of ACE inhibitors
in patients with intermittent claudication is unknown, the magnitude of
beneﬁt demonstrated here exceeds that of the U.S. Food and Drug Admin-
istration-approved drugs for treatment of intermittent claudication. Logi-
cally, the next step would be a head-to-head comparison of ramipril and
cilostazol in the medical management of intermittent claudication.Evolving Patterns of Vascular Surgery Care in the United States: A
Report From the American Board of Surgery
Valentine RJ, Rhodes RS, Jones A, et al., the Members of the Vascular
Surgery Board of the American Board of Surgery. J Am Coll Surg
2013;216:886-93.
Conclusion: Most general surgeons do not perform any major
vascular procedures. Younger general surgeons are performing fewer such
procedures than their older counterparts. The opposite is true for vascular
surgeons.
Summary: A 2011 report on general surgery workloads and practice
patterns in theUnited States indicated that a substantial proportion of general
surgical procedures are performed by subspecialists and that general surgeons276were still performing a considerable number of specialty operations, including
vascular surgery operations (Valentine RJ et al, Ann Surg 2011;254:520-6).
However, because endovascular procedures are now accepted options for
some open vascular operations and general surgery residents receive little
training in endovascular techniques and progressively less open operative
vascular experience, it would be reasonable to assume fewer vascular surgery
procedures are performed by practicing general surgeons. This report sought
to detail the effect of changes in vascular surgery on the practice patterns of
general surgeons. The authors sought to evaluate the type of vascular proce-
dures performed by general surgeons and to compare practices of vascular
surgeons vs general surgeons at different points in their careers. The over-
arching goal was to assess over all trends in the pattern of vascular surgical
care. Case logs of surgeons seeking recertiﬁcation in surgery from 2007 to
2009 were reviewed. Data from 3362 physicians certiﬁed only in general
surgery were compared with 363 also certiﬁed in vascular surgery. Indepen-
dent variables were compared using factorial and analysis of variance. General
surgeons performed a mean number of 10 6 51 major vascular procedures,
whereas vascular surgeons performed a mean number of 192 6 209 major
vascular procedures (P < .001). Of the total vascular procedures performed,
31% were performed by general surgeons. Compared with vascular surgery,
general surgeons performed signiﬁcantly fewer vascular procedures in all
major procedure categories. General surgeons recertiﬁed at 10 years per-
formed fewer vascular procedures (6.7 6 47) than those recertifying at 20
years (11.56 48) and 30 years (13.66 59; P< .01). Vascular surgeons certi-
fying at 10 years performedmore vascular procedures (2356 237) compared
with those recertifying at 20 years (1576 173) and 30 years (1046115). The
mean number of vascular procedures performed was not different for sex,
geographic location, or practice type after controlling for other variables.
Comment: The opposing trends in vascular procedures performed by
general surgeons and vascular surgeons indicate vascular procedures are
shifting from general surgery to vascular surgery in modern surgical practice.
This is not particularly surprising. The shift away from general surgeons per-
forming vascular operations is probably even more dramatic than indicated.
Vascular operations performed by cardiothoracic surgeons, osteopathic
surgeons, transplant surgeons, and endovascular procedures performed by
cardiologists and interventional radiologists were not included in the data
analysis. The higher work load of younger vascular surgeons, compared
with older vascular surgeons, suggests there may be limited capacity for
vascular surgery as a specialty to capture more of the overall market for
vascular surgical procedures without increasing the number of trainees.Females With Subclavian Vein Thrombosis May Have an Increased
Risk of Hypercoagulability
Likes K, Rochlin D, Nazarian SM, et al. JAMA Surg 2013;148:44-9.
Conclusion: Young women with spontaneous subclavian/axillary
vein thrombosis should be considered for testing for the presence of a hyper-
coagulable state.
Summary: The prevalence of hypercoagulability in patients with axillo-
subclavian vein thrombosis is debated. Primary axillosubclavian vein throm-
bosis is generally related to a lesion in the subclavian vein that consistently
occurs w1 cm outside the subclavian jugular vein junction. Whether this is
secondary to purely anatomic factors, the combination of an anatomic factors
and activity, or activity alone, is debated. Because not all patients with primary
subclavian axillary vein thrombosis have a history of signiﬁcant activity and
a few may not have the usual underlying anatomic abnormality, a hypercoag-
ulable state may possibly play a role in the development of spontaneous axil-
losubclavian vein thrombosis in some cases. In this study, the authors
reviewed their patients tested for hypercoagulability who presented to their
institution with subclavian/axillary vein thrombosis. This was a retrospective
analysis of a database that contains patients from August 2003 to June 2011.
According to the authors, patients were tested for hypercoagulability if they
presented with axillary/subclavian vein thrombosis not associated with signif-
icant activity. What constituted signiﬁcant activity was not clearly deﬁned. In
addition to hypercoagulability testing, patients were also reviewed for short-
term anatomic ﬁndings and clinical outcomes. During the study interval, 143
patients presented with primary axillary/subclavian vein thrombosis. They
were a mean age of 32 years (range, 16-71 years). Of these patients, 55 (43
